4-PrO-DMT is not named in the DEA's August 2026 lists, but the Federal Analogue Act can still reach an unlisted psilocin analogue intended for human use.
4-PrO-DMT is not listed by name in the August 2026 federal schedules of controlled substances, but it is not necessarily legal to sell, buy, or possess for human use. The Drug Enforcement Administration (DEA) explains that an unlisted chemical can still be treated as a controlled substance under federal law, specifically through the Federal Analogue Act when intended for human consumption. Whether any particular case involving 4-PrO-DMT satisfies those federal statutory tests is decided case by case in court.
At The Psychedelic Journal, we reviewed the DEA controlled substance lists and peer-reviewed pharmacology to clarify where 4-PrO-DMT stands under federal law. 4-PrO-DMT, also known as 4-propionoxy-N,N-dimethyltryptamine, is, in the 2023 paper's words, an obscure new psychoactive substance (NPS) sold on recreational drug markets, structurally related to psilocin and psilocybin. The study we reviewed is a laboratory and mouse study, and no human clinical trial appears in the sources reviewed.
4-PrO-DMT is not explicitly scheduled by name under federal law, but that absence from official lists does not make it legal to manufacture, distribute, or possess. In the August 2026 edition of the DEA Diversion Control Division's Lists of: Scheduling Actions, Controlled Substances, Regulated Chemicals, known as the Orange Book, 4-PrO-DMT does not appear anywhere in the schedules. By contrast, psilocybin (drug code 7437) and psilocin, also spelled psilocyn (drug code 7438), are listed as Schedule I controlled substances.
The DEA provides an explicit warning in the foreword of the August 2026 lists regarding unlisted substances. The DEA explains that its published lists describe basic or parent chemicals and do not comprehensively cover every salt, isomer, ester, ether, or derivative that might be controlled. The agency states directly that a substance need not be listed as a controlled substance to be treated as a scheduled substance for criminal prosecution. The lists alone therefore support neither 'legal' nor 'Schedule I drug'.
Individuals or organizations seeking formal confirmation of a compound's regulatory position can seek agency clarification. The DEA foreword notes that outside parties who want to ensure that a compound is not considered a scheduled substance or listed chemical should write to the DEA Drug and Chemical Evaluation Section, Diversion Control Division, for an official determination. We have not requested or received any such administrative determination for 4-PrO-DMT. To understand how federal law treats other psychedelics, you can read our guide on what psychedelics are legal in the US.
Federal prosecutors can regulate unlisted chemicals using the Federal Analogue Act. According to the foreword of the DEA Orange Book, a controlled substance analogue is a substance intended for human consumption that meets specific statutory criteria. The foreword lists these elements: intended for human consumption, structurally substantially similar to a Schedule I or II substance, pharmacologically substantially similar to one or represented as similar to one, and not an approved medication in the United States. The exact test is the text of 21 U.S.C. § 802(32)(A).
The statutory definition of an analogue appears in 21 U.S.C. § 802(32)(A), and its legal treatment is established in 21 U.S.C. § 813. Under Section 813, a controlled substance analogue intended for human consumption is treated, for the purposes of any federal law, as a controlled substance in Schedule I. Whether a given case meets that test is decided case by case.
We found no published court ruling, published DEA determination, or official judicial precedent resolving whether 4-PrO-DMT qualifies as a controlled substance analogue under federal law. A court's answer is unknown. Our guide on 4-AcO-DMT, another psilocin prodrug, explains that 4-AcO-DMT is also unlisted on federal schedules, but federal prosecutors have brought 4-AcO-DMT cases under the Federal Analogue Act as a psilocin analogue. None of this constitutes a legal finding regarding 4-PrO-DMT specifically.
4-PrO-DMT is an abbreviation for the chemical compound 4-propionoxy-N,N-dimethyltryptamine. In chemical structure, it belongs to the tryptamine class and carries a propionoxy functional group attached to the 4-position of its indole ring core.
The relationship between 4-PrO-DMT and other psychedelic tryptamines centers on that 4-position modification. Psilocin (4-hydroxy-N,N-dimethyltryptamine) carries a simple hydroxy group at the 4-position, while 4-AcO-DMT (4-acetoxy-N,N-dimethyltryptamine) carries an acetoxy group at that identical site. Psilocybin carries a phosphoryloxy group at the 4-position.
In a peer-reviewed 2023 study published in ACS Pharmacology & Translational Science, Glatfelter and colleagues characterized 4-PrO-DMT as an obscure new psychoactive substance (NPS) sold on recreational drug markets with little information available concerning its pharmacological activity. The researchers noted that, similar to 4-AcO-DMT and psilocybin, it has been postulated that 4-PrO-DMT functions as a prodrug for psilocin. The study concluded that 4-PrO-DMT could be an active prodrug for psilocin in living organisms depending on the rate of in vivo enzymatic hydrolysis.
Formal scientific evaluation of 4-PrO-DMT is limited; the 2023 paper itself says little information was available, with the primary laboratory characterization conducted in a 2023 study by Glatfelter and colleagues. The investigators evaluated in vitro receptor binding profiles for several tryptamine psychedelics with different 4-position substituents and different dialkyl groups. Their assays showed that these tryptamines interact with multiple serotonin receptors, including the serotonin 1A receptor subtype. The 4-acetoxy and 4-propionoxy analogues of 4-hydroxy compounds exhibited somewhat weaker receptor binding affinities than their parent molecules, but they displayed similar overall target profiles across the serotonin system.
The 2023 paper also examined the behavioral consequences of 4-PrO-DMT administration in living mice. When administered subcutaneously at doses ranging from 0.3 to 3 mg/kg, 4-PrO-DMT produced a dose-related head-twitch response mediated by activation of serotonin 2A (5-HT2A) receptors. At higher doses ranging between 3 and 30 mg/kg, 4-PrO-DMT produced hypothermia and reduced locomotor activity mediated by serotonin 1A (5-HT1A) receptor activation.
The authors of the study observed that recreational consumption of 4-PrO-DMT has been reported in humans, but their paper represents a laboratory and animal investigation rather than a clinical trial. There are no published controlled human clinical trials of 4-PrO-DMT in the sources reviewed. Mouse experimental doses cannot be converted or applied to human use.
4-PrO-DMT shares a common pharmacological concept with 4-AcO-DMT and psilocybin: all three compounds share an identical N,N-dimethyltryptamine core while varying only in the ester or phosphate group bound to the 4-position. Psilocybin is 4-phosphoryloxy-N,N-dimethyltryptamine, the naturally occurring compound found in psilocybin mushrooms that is scheduled federally under Schedule I.
4-AcO-DMT carries an acetoxy group, whereas 4-PrO-DMT carries a propionoxy group at that same position. The Glatfelter study describes 4-PrO-DMT as a psilocybin analogue. In the 2023 study, 4-acetoxy and 4-propionoxy analogues of 4-hydroxy compounds showed somewhat weaker binding affinities but similar target profiles across serotonin receptors.
While psilocybin is an explicitly listed federal Schedule I drug, both 4-AcO-DMT and 4-PrO-DMT are absent from the August 2026 DEA lists. For broader context on federal scheduling frameworks, see our guide to legal psychedelics in the US.
State drug laws do not always duplicate federal controlled substance schedules. State law on unlisted tryptamines varies, and some states schedule specific compounds or whole chemical classes. Consequently, an unlisted status at the federal level does not ensure that a substance is unscheduled under state criminal codes.
We make no state-by-state legality claims regarding 4-PrO-DMT, because we have not checked any state's statute for it. Furthermore, the state-level legal status of sibling compounds cannot be assumed to apply to 4-PrO-DMT. For example, while Florida, Georgia, and Louisiana have explicitly scheduled 4-AcO-DMT in their state statutes, those legislative actions do not establish whether those states have also added 4-PrO-DMT by name.
Readers tracking state-level legislative changes regarding natural psilocybin can consult our legal status by state guide and our psychedelic legal map for broader statutory context on psychedelic policy reforms across the country.
Scientific and legal reference materials leave gaps regarding 4-PrO-DMT. The one laboratory study we reviewed used in vitro receptor binding assays and mice, and no human clinical trial of 4-PrO-DMT appears in the sources reviewed.
From a regulatory perspective, absence from the DEA Orange Book is not a legal clearance. If you want an official answer on whether 4-PrO-DMT is considered a scheduled substance or listed chemical, the DEA foreword says to write to the DEA Drug and Chemical Evaluation Section, Diversion Control Division.
4-PrO-DMT is not explicitly listed in the DEA schedules of controlled substances, but it is not necessarily legal. Under the Federal Analogue Act, an unlisted chemical intended for human consumption can be treated as a Schedule I controlled substance if it meets the analogue definition the DEA describes. Whether 4-PrO-DMT meets that standard in a criminal prosecution is decided case by case.
4-PrO-DMT is not listed as a Schedule I controlled substance by name in the August 2026 DEA Orange Book. However, the DEA explicitly notes that a substance does not need to be listed to be treated as a scheduled drug under the law. Federal prosecutors can treat unlisted compounds as Schedule I substances if they satisfy the criteria of the Federal Analogue Act.
No, 4-PrO-DMT and 4-AcO-DMT are distinct chemical compounds, though they are close structural relatives. 4-PrO-DMT possesses a propionoxy group at the 4-position of its indole ring, whereas 4-AcO-DMT carries an acetoxy group at that position. Both substances are postulated to function as metabolic precursors to psilocin in living systems.
The 2023 Glatfelter study says 4-PrO-DMT could be an active prodrug for psilocin, depending on the speed of enzymatic hydrolysis in vivo. That remains a postulated mechanism rather than a settled fact, and no human clinical trial of 4-PrO-DMT appears in the sources reviewed.
No human clinical trial of 4-PrO-DMT appears in the sources we reviewed. The one laboratory study we found, published in 2023, used in vitro receptor binding assays and mice.
No state statute has been checked for 4-PrO-DMT. State drug laws vary widely, and some states schedule broad structural classes of tryptamines or name specific novel analogues. A lawyer can advise on a specific situation.
Get psilocybin research & policy updates
New trials, FDA decisions, and legal changes for psilocybin — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.